Sign in

    Neil Cataldi

    Research Analyst at Cantor Fitzgerald

    Neil Cataldi's questions to Marpai (MRAI) leadership

    Neil Cataldi's questions to Marpai (MRAI) leadership • Q1 2025

    Question

    Neil Cataldi of Harbor Access inquired about Marpai's sales strategy for accelerating growth after lower-than-expected new business in Q1, the path to achieving cash flow positivity by year-end given the $3 million burn in the first quarter, and for more details on the new Empara Member Portal and its benefits.

    Answer

    Steve Johnson, an executive at Marpai, explained that the 2024 focus was on operational turnaround, with key sales staff hired mid-year. He anticipates off-cycle client wins in H2 2025, including new school districts, and a stronger January 2026 cycle. Regarding cash burn, Johnson cited upcoming savings from rationalizing vendors, ending legacy contracts, and driving operational efficiencies, noting a significant reduction in cash burn is expected in Q2. He described the Empara Portal as a unified, AI-powered application that allows members to get automated answers to benefit questions by searching plan documents, which reduces call center volume and improves customer service by providing agents with prior context if a call is needed.

    Ask Fintool Equity Research AI

    Neil Cataldi's questions to STREAMLINE HEALTH SOLUTIONS (STRM) leadership

    Neil Cataldi's questions to STREAMLINE HEALTH SOLUTIONS (STRM) leadership • Q4 2024

    Question

    Neil Cataldi of Cantor Fitzgerald inquired about the go-to-market strategy for the new denials prevention functionality, the significant improvements in implementation timelines for eValuator, and the company's confidence in future bookings momentum.

    Answer

    Ben Stilwill, President and CEO, explained that the new denials prevention feature is a core enhancement to the eValuator platform, designed to use payer denial data to make claims 'bulletproof' before submission. He noted that implementation times have dramatically improved due to process standardization, with eValuator projects now averaging 2-3 months, down from 4-6 months previously, and similar improvements being applied to RevID. Stilwill expressed confidence in building sales momentum by leveraging client success stories and peer-to-peer marketing, which is already increasing top-of-funnel activity.

    Ask Fintool Equity Research AI

    Neil Cataldi's questions to STREAMLINE HEALTH SOLUTIONS (STRM) leadership • Q4 2025

    Question

    Neil Cataldi of Requiem Capital inquired about the new denials prevention functionality, its impact on the customer base and eValuator's marketability, the significant improvement in implementation timelines, and the company's confidence in building sales momentum after recent changes to the sales force.

    Answer

    Ben Stilwill, President and CEO, detailed that the new denials prevention feature leverages payer data pre-bill to make claims 'bulletproof,' which has been met with excitement from clients. He confirmed that implementation times for eValuator have dramatically decreased from 4-6 months to under 3 months due to process standardization, a playbook now being applied to accelerate RevID implementations as well. Stilwill expressed confidence in future bookings, citing a strategy focused on peer-to-peer marketing and client success stories, which is already generating increased top-of-funnel activity.

    Ask Fintool Equity Research AI